ClinicalTrials.gg
TerminatedNCT02749825Updated Apr 25, 2016

Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate Cancer

A Phase 4 interventional study of Trelstar and Lupron in Prostate Cancer, sponsored by Pharmatech. Terminated at 11 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-04-25.

Sponsored by Pharmatech · Phase 4, Interventional, and Treatment

Why this study was terminated
Withdrawal of funding support

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing triptorelin in Prostatic Neoplasms — 6 open to participants now, 6 under way, 3 of them phase 3. triptorelin · Prostatic Neoplasms.

Enrollment
22nd of 28
41 · median 120
Started
2002
the only one that year
Phase 4
6 of 28
none open now
Registered
11th of 28
by date

Among the 28 studies testing triptorelin in Prostatic Neoplasms, this one is the 22nd largest by enrollment, is the only one that started in 2002, is one of 6 in phase 4, and was the 11th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

6 of the 28 studies testing triptorelin in Prostatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About triptorelin

triptorelin: first FDA approval 2000 (TRELSTAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing triptorelin in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This research study looks at Testosterone levels in patients receiving Trelstar versus those receiving Lupron or Zoladex. These drugs have been approved for treatment of Prostate Cancer by the FDA.

Read the detailed description

Patients who are currently receiving Lupron or Zoladex will be consented and then randomized to receive either continued treatment with the drug they have been on, or will be randomized to Trelstar for a period of 3 months. At the end of that period, testosterone and prostate serum antigen (PSA) levels will be drawn and compared to their previous levels to determine if Trelstar is as effective as the previous treatment.

03

Conditions studied

  • Prostate Cancer

Keywords

  • Prostate
  • Cancer
  • Trelstar
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Advanced Prostate Cancer
  • Currently taking Lupron or Zoladex
  • Stable PSA
  • Baseline testosterone below castration level
  • > 6 months
  • performance status of 0-2
  • Signed, approved .

Exclusion criteria

Exclusion Criteria:

  • Known to any leuteinizing hormone releasing hormone (LHRH) agonist
  • Ongoing therapy with hyperprolactinemic agents
  • Antiandrogen therapy within 28 days prior to study start
  • Prior Orchiectomy, hypophysectomy or adrenalectomy
  • Chemotherapy, radiotherapy, or prostatectomy within 28 days prior to study start
  • Use of any agent 3 months prior to enrollment
  • Use of systemic within 28 days or during study
  • Other within 2 yrs prior to study start, except curatively treated skin cancers
  • Severe kidney or liver failure, based on adequate lab values
  • Other medical conditions which would be likely to interfere with compliance or completion of study requirements
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Trelstar

    Per prescribing information

    Drug: Trelstar

  • Active comparator
    Lupron

    Per prescribing information

    Drug: Lupron

  • Active comparator
    Zoladex

    Per prescribing information

    Drug: Zoladex

Interventions

  • As labeled

    Also known as: Triptorelin pamoate

  • DrugLupron

    As labeled

    Also known as: luprolide acetate for depot suspension

  • As labeled

    Also known as: goserelin acetate

06

What researchers measure

Primary outcomes

  1. Maintenance of serum testosterone at or below castration level (50ng/dL)

    Primary efficacy

    Time frame: 12 weeks

Secondary outcomes

  1. Serum testosterone level at end of study

    Secondary efficacy

    Time frame: Week 12

  2. Change in serum testosterone from baseline to end of study

    Secondary efficacy

    Time frame: Baseline and week 12

  3. Incidence and severity of adverse events

    Treatment tolerability

    Time frame: 12 weeks

07

Study locations

11 sites
  • Arizona Urologic Specialists
    Tucson, Arizona 85712-5803, United States
  • Heritage Physician Group - Urology Department
    Hot Springs, Arkansas 71913, United States
  • California Oncology of the Central Valley
    Fresno, California 93710, United States
  • San Bernardino Urological Associates Medical Group
    San Bernardino, California 92404, United States
  • UroSearch
    Ocala, Florida 34470, United States
  • Scott A Slavis, MD, PC
    Las Vegas, Nevada 89109, United States
  • Shaukat M Qureshi, MD
    Pennsville, New Jersey 08070, United States
  • Brooklyn Heights Urology Associates
    Brooklyn, New York 11201, United States
  • Jazrawi-Atallah, P.C.
    Brooklyn, New York 11201, United States
  • Albemarle Urology Clinic, PA
    Albemarle, North Carolina 28001, United States
  • Raj P. Chopra MD, PC
    Bloomsburg, Pennsylvania 17815, United States
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2002, a primary completion of May 2006 and a completion of Jul 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2012
First posted
Apr 25, 2016
Start
Sep 2002
Primary completionActual
May 2006
CompletionActual
Jul 2006
Last update
Apr 25, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02749825
Lead sponsor
Pharmatech
Collaborators
Manyak, Michael, M.D., Watson Pharmaceuticals
Responsible party
Sponsor
First posted
Apr 25, 2016
Start date
Sep 2002
Primary completion
May 2006
Completion
Jul 2006
Last update
Apr 25, 2016

Study contacts

Michael Michael Manyak, MD
principal investigator · Georege Washington University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Triptorelin

Start the discussion